The clinical and photobiological characteristics of solar urticaria in 40 patients
The clinical and photobiological characteristics of solar urticaria in 40 patients
复制标题
日光性荨麻疹40例临床及光生物学特征
DOI：
10.1046/j.1365-2133.2000.03238.x
复制
发表时间：
2000
影响因子：
10.3
通讯作者：
T. Horio
中科院分区：
文献类型：
--
作者：
N. Uetsu;H. Miyauchi‐Hashimoto;H. Okamoto;T. Horio
本文报告了25年来40例日光性荨麻疹患者的体检结果。 出现症状时的中位年龄为32岁，范围为13至76岁。 最常见的（45%）日光性荨麻疹首次出现在第三个十年。平均病程为3.6年。 24例患者（60%）的作用光谱在可见光范围内，4例在紫外线（UV）A范围内，4例在UVB范围内，3例从UVA到UVB，1例从UVA到可见光，4例在UVB到可见光的宽范围内。在19名患者中的13名（68%）中检测到抑制光谱，其中12名患者的波长比作用光谱长。增强光谱被发现在14例（29%）检查中只有4。31例患者中有24例（77%）对自体血清发生荨麻疹反应，该自体血清先前已在该患者的作用谱下进行体外辐照。在一个单一的病人，日光性荨麻疹是由药物，即氯丙嗪。在两名患者中，多形性日光疹发生与日光性荨麻疹。没有一种单一的治疗方法是令人满意的，但联合使用抗组胺药，日光浴，pepsilen UVA光化学疗法和/或防晒剂部分抑制症状。
Forty patients with solar urticaria, 16 male and 24 female, were examined personally during the past 25 years. The median age at onset of symptoms was 32 years, ranging from 13 to 76 years. Most commonly (45%) solar urticaria first appeared during the third decade. The mean duration of the disease was 3·6 years at presentation. The action spectrum was found in the visible light range in 24 patients (60%), in the ultraviolet (UV) A range in four, in the UVB in four, from the UVA to UVB in three, from the UVA to visible light in one and in a broad range from UVB to visible light in four patients. An inhibition spectrum was detected in 13 of 19 patients (68%), occurring at longer wavelengths than the action spectrum in 12 of these cases. The augmentation spectrum was found in only four of 14 patients (29%) examined. Twenty‐four of 31 patients (77%) developed an urticarial reaction to autologous serum, which had been previously irradiated in vitro at the action spectrum for that patient. In a single patient, solar urticaria was caused by a drug, namely chlorpromazine. In two patients, polymorphic light eruption occurred in association with solar urticaria. No single modality of treatment was satisfactory, but combined use of antihistamines, sunbathing, psoralen UVA photochemotherapy and/or sunscreening agents partially suppressed the symptoms.